Rein Therapeutics Inc. (Nasdaq: RNTX) has received U.S. Food and Drug Administration Fast Track designation for LTI-03, its investigational treatment for idiopathic pulmonary fibrosis. The company announced the designation on August 20, 2026, while enrolling patients in its global Phase 2 RENEW trial.
Fast Track designation is intended to facilitate the development and review of therapies that address serious conditions and unmet medical needs. It can provide more frequent communication with the FDA and may permit sections of a future marketing application to be submitted on a rolling basis. A qualifying program may also be considered for Accelerated Approval or Priority Review if it meets the applicable requirements.
The designation does not represent FDA approval of LTI-03 or confirm that the treatment is safe or effective.
LTI-03 is an inhaled synthetic peptide derived from Caveolin-1 biology. Rein is developing the candidate to inhibit profibrotic signaling while protecting alveolar progenitor cells involved in repairing lung tissue. Idiopathic pulmonary fibrosis is a progressive disease in which scar tissue accumulates in the lungs and gradually reduces their ability to function.
The RENEW trial is a randomized, placebo-controlled Phase 2 study expected to enroll approximately 120 patients across the United States, United Kingdom, Australia, Germany and Poland. Participants will receive one of two LTI-03 dose levels or a placebo.
The trial’s primary safety endpoint measures treatment-emergent adverse events through Week 24. Its primary efficacy endpoint assesses changes in forced vital capacity, a standard measurement of lung function. Rein reported on August 14 that enrollment had passed 25% of the planned total and remained on track for interim data during the second half of 2026.
CEO Brian Windsor called the Fast Track designation “a significant milestone for Rein” and said it could allow the company to work more closely with the FDA during development.
The program has previously encountered regulatory delays. The FDA placed the U.S. portion of the RENEW trial under a full clinical hold in 2025. The agency lifted that hold in November after reviewing the company’s Complete Response submission and determining that the study could resume.
Rein reported $43.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, alongside a second-quarter net loss of $6.4 million. The company expects its available capital to support operations into the first quarter of 2028 and fund completion of RENEW.
That balance followed a May public offering involving 57.5 million new shares priced at $1 each. The offering strengthened Rein’s financial position but substantially increased its outstanding share count and diluted existing stockholders.
Upcoming Catalysts
The principal upcoming catalyst is interim RENEW data expected during the second half of 2026. Additional milestones could include further enrollment updates, FDA discussions enabled by the Fast Track designation and details about the program’s subsequent clinical or regulatory path.
Sources
- Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 — GlobeNewswire, August 20, 2026
- Rein Therapeutics Reports Second-Quarter 2026 Results — Rein Therapeutics, August 14, 2026
- RENEW Phase 2 Trial Record, NCT06968845 — ClinicalTrials.gov
- FDA Clears Rein to Resume the U.S. RENEW Trial — Rein Therapeutics, November 3, 2025
- Rein Therapeutics Form 10-Q for the Quarter Ended March 31, 2026 — SEC
- Rein Therapeutics Closes $57.5 Million Public Offering — Rein Therapeutics, May 18, 2026
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, SEC filings and the federal clinical-trial registry. Securities discussed or referenced include Rein Therapeutics Inc. (Nasdaq: RNTX). Biotech Stocks Daily has not received compensation from Rein Therapeutics, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used include Rein Therapeutics’ August 20, 2026 Fast Track announcement, its August 14, 2026 financial and clinical update, its November 3, 2025 clinical-hold update, its May 18, 2026 financing announcement, ClinicalTrials.gov and the company’s SEC Form 10-Q for the quarter ended March 31, 2026. Information concerning LTI-03’s mechanism, clinical potential and expected milestones originated primarily from Rein and has not been independently validated by Biotech Stocks Daily.
LTI-03 remains investigational. Fast Track designation does not constitute FDA approval and does not establish safety, efficacy or a favorable review outcome. The RENEW trial may encounter enrollment, safety, regulatory or operational delays, and its results may not support further development. The FDA previously placed the U.S. study under a clinical hold, which it lifted in November 2025.
Financial information reflects the dates of the cited disclosures and may have changed. Rein has not generated revenue from product sales and expects continued operating losses. Its May 2026 public offering strengthened its cash position but involved 57.5 million new shares and caused substantial dilution. The company’s projected cash runway into the first quarter of 2028 is a forward-looking estimate.
Biotechnology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
